Frequently Asked Questions

  1. What is BriaCell™ Therapeutics Corp.’s business?

    BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.

    BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with the immunotherapy development candidates INCMGA00012, an anti-PD-1 antibody, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (both provided by Incyte)*. The combination study is listed in ClinicalTrials.gov as NCT03328026.

    BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients.

    BriaCell recently announced Grant to Investigator, Dr. Saveri Bhattacharya, at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa * Combination Study of Bria-IMT™ with KEYTRUDA® [manufactured by Merck & Co., Inc. (NYSE: MRK)]* in advanced breast cancer. Merck will provide KEYTRUDA® for use in the Combination Study. For additional information, please directly contact the study coordinator, Ms. Rita Murphy, at Rita.Murphy@jefferson.edu.

    BriaCell is also developing Bria-OTS™ *, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

    * The continuation and completion of these studies depends on BriaCell securing adequate capital to execute these studies.

  2. What is BriaCell™ Therapeutics Corp.’s ticker symbol, exchange, and CUSIP?

    BriaCell™ Therapeutics Corp.’s ticker is BCTXF, and traded on OTCQB. It CUSIP number is 10778Y104. BriaCell™ Therapeutics Corp. also trades on TSX Venture exchange (BCT.V) and its CUSIP number is 10778, and at Burse Frankfurt (8BTA).

  3. When was BriaCell™ Therapeutics Corp. founded?

    BriaCell™ Therapeutics Corp. was incorporated as a private Delaware company on April 3, 2014. On November 27, 2014, BriaCell™ Therapeutics Corp. completed it’s Initial Public Offering (IPO), raised $US2.0 million, and began trading at TSX Venture (BCT.V). BriaCell™ Therapeutics Corp. is currently listed on OTCQB (BCTXF), and on Burse Frankfurt (8BTA).

  4. How many of the Company’s shares are outstanding?

    As of September 22, 2020, 771.96K of the Company’s shares were outstanding.

  5. When is the next earnings release?

    BriaCell™ Therapeutics Corp.’s quarterly earnings reports are tentatively scheduled to be released prior to 60 days following a quarter-end and prior to 120 days following the year-end. All earnings releases are posted on our Web site.

  6. What are BriaCell™ Therapeutics Corp.’s fiscal year and corresponding quarter-end dates?

    We operate on a fiscal year that runs from Aug 1 to July 31. Quarter-ends are: Oct 31 (Q1), Jan 31 (Q2), April 30 (Q3) and July 31 (Q4).

  7. How can I get on an e-mail list to receive all press releases?

    To automatically receive e-mail alerts for the information categories that interest you, please click on E-mail Alerts and submit your e-mail address.

  8. Who are BriaCell™ Therapeutics Corp.’s Independent Chartered Public Accountants?

    MNP LLP, Chartered Accountants, is BriaCell™ Therapeutics Corp.’s independent auditor.

  9. Who is BriaCell™ Therapeutics Corp.’s transfer agent and registrar?

    Computershare Investor Services Inc. currently acts as the Company’s transfer agent and registrar.